OKYO Pharma Limited
OKYO
ISIN GG00BMFG5F62 / Valor 127195533
OKYO Pharma Limited
UMushroom community rating:
About company
OKYO Pharma Limited is a biotechnology company focused on developing therapies for inflammatory dry eye diseases and chronic pain management.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (09.10.2025):
OKYO Pharma Limited reported its financial results for the twelve months ended March 31, 2023, highlighting significant advancements in its clinical trials for OK-101, despite an increase in net losses and research and development expenses.
Net Loss Increased
For the twelve months ended March 31, 2023, OKYO Pharma Limited reported a net loss of $13.7 million, compared to a loss of $6.3 million for the same period in 2022.
R&D Expenses Rose Significantly
Research and development expenses surged to $6.3 million for the twelve months ended March 31, 2023, up from $1.6 million in the previous year, primarily due to efforts in filing an IND for OK-101 in treating dry eye disease.
Improved Cash Position
OKYO ended the twelve-month period with $4.0 million in cash as of March 31, 2023, an increase from $2.7 million on March 31, 2022.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
81 M
Market cap (USD)
82,224
Daily traded volume (Shares)
1.2 / 1.18
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Diana Costa
Diana Costa
Diana Costa
EQUITIES OF THE SAME SECTOR
